Aldara Related Published Studies
Well-designed clinical trials related to Aldara (Imiquimod)
Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. [2011.10]
Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. [2011.07]
Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. [2011.04]
Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. [2011.03]
Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. [2011.02]
A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. [2011.02]
Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years
median follow-up of a randomized clinical trial. [2011]
A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. [2010.09.24]
Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. [2010.07.01]
Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. [2010.07]
Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). [2010.06.11]
The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. [2010.04.21]
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. [2010.04]
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. [2010.04]
A double-blind, randomized controlled trial of the use of imiquimod cream for the
treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive
MSM on HAART, with long-term follow-up data including the use of open-label
imiquimod. [2010]
Topical imiquimod in conjunction with Nd:YAG laser for tattoo removal. [2009.11]
Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. [2009.10]
Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. [2009.05]
Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. [2009.01]
Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. [2009.01]
Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. [2008.07]
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. [2008.04.03]
Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. [2008.04]
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2008.04]
A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. [2008]
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2007.12.06]
Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. [2007.11]
Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. [2007.11]
A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. [2007.10]
Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. [2007.08]
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. [2007]
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. [2006.12]
An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. [2006.07]
Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. [2006.06]
Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. [2006.01]
Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. [2006.01]
Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. [2005.11]
Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. [2005.09.15]
Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. [2005.08]
Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. [2005.06]
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. [2005.05]
Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. [2005.04]
5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. [2004.12]
[Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients] [2004.11]
Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. [2004.10]
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. [2004.09]
Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. [2004.08]
Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. [2004.08]
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. [2004.05]
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. [2004.05]
Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. [2003.11]
Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. [2003.02]
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. [2002.12]
A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. [2002.11]
Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. [2002.10]
Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. [2002.10]
Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. [2002.09.02]
Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. [2002.09]
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. [2002.09]
Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. [2001.05]
Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. [2001.04]
Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. [2001.01]
Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. [2000.10]
Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. [2000.09]
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. [2000.07]
A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. [1999.12.03]
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. [1999.12]
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. [1999.08]
A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. [1998.08]
Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts. [1998.07.01]
Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. [1998.07]
Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. [1998.05]
Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. [1998.04]
Treatment of genital warts with an immune-response modifier (imiquimod). [1998.02]
Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. [1998.01]
Well-designed clinical trials possibly related to Aldara (Imiquimod)
Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. [2010.03.11]
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. [2009.06.15]
Other research related to Aldara (Imiquimod)
Treatment of cervical intraepithelial neoplasia with topical imiquimod: a
randomized controlled trial. [2012]
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without
tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by
conservative staged excisions. [2012]
Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal
cell carcinoma in the face: a prospective randomized controlled study. [2012]
Results of an investigator-initiated single-blind split-face comparison of
photodynamic therapy and 5% imiquimod cream for the treatment of actinic
keratoses. [2012]
Randomized clinical trial of imiquimod: an adjunct to treating cervical
dysplasia. [2012]
Immunomodulation by imiquimod in patients with high-risk primary melanoma. [2012]
Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. [2011.09.15]
Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells. [2011.08.15]
Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. [2011.07.13]
Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. [2011.07]
Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases. [2011.07]
Failure of extensive extramammary Paget disease of the inguinal area to clear with imiquimod cream, 5%: possible progression to invasive disease during therapy. [2011.06]
Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer. [2011.06]
Treatment of giant Bowen's disease with sequential use of photodynamic therapy and imiquimod cream. [2011.06]
Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. [2011.06]
Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. [2011.06]
Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. [2011.06]
Imiquimod 5% cream for the treatment of nasal lesion of metastatic renal cell carcinoma. [2011.05]
A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. [2011.05]
Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. [2011.04]
Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection. [2011.03]
Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. [2011]
Cryosurgery is more effective in the treatment of primary, non-superficial basal
cell carcinomas when applied during and not prior to a five week imiquimod
course: a randomized, prospective, open-label study. [2011]
Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid
basal cell carcinoma. [2011]
|
